San Diego’s ViaCyte is clearly up to plenty – the regenerative medicine company just announced it has teamed up with Janssen Research & Development, securing $20 million in financing in the process. As part of the deal, the pharma giant gains rights to evaluate clinical efficacy of ViaCyte’s Type 1 diabetes treatment – an artificial […]
New York regenerative medicine startup EpiBone‘s tagline is apt: “Grow your own bone.” It uses a patient’s own stem cells to create transplantable, highly personalized bone grafts, going after a 900,000-strong market of patients that need some variety of bone graft to treat, say, severe bone trauma, growth defects or genetic disorders. The company is showcased as one […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Edited to include comments from CEO. Halfway through its first large-scale efficacy trial, Athersys’s experimental stem cell therapy did not provide significant benefit to patients with moderate-to-severe ulcerative colitis. But the company isn’t too worried about what that might mean just yet. Cleveland-based Athersys (NASDAQ: ATHX) released the interim results today for the Phase 2 […]
Athersys (NYSE:ATHX) is looking to Japan for potential opportunities to bring its MultiStem therapies to market quicker. In its annual financial results call on Thursday, Athersys’ chief operating officer, BJ Lehmann, explained that legislation passed last fall in Japan could allow for conditional approval of new regenerative medicines that demonstrate strong safety profiles in clinical […]
Rather than leveraging stem cells for therapeutic use, iPierian Inc. has been using them to create disease models with which is can screen and develop new drugs. Now, with $30 million it’s just collected from investors, iPierian Inc. plans to split two distinct R&D programs that have emerged from those techniques into different companies. Some […]
Once the healthcare innovator’s guide to must-know tech terms for the next decade of medicine hit on Monday, the feedback started coming in. It’s continued to trickle in via email, Twitter and LinkedIn all week. (Thank you!) MedCity News readers had some interesting ideas about technologies they think everyone in the healthcare space needs to […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
A closed-loop system of devices referred to as the artificial pancreas has been called the “holy grail” for Type 1 diabetes. Some scientists, though, think the future of diabetes treatment lies not in glucose meters and insulin pumps but in cell-based therapies with the potential to eliminate the need for daily insulin injections. Islet cell […]
StemBioSys, a San Antonio company that manufactures and develops stem cell technologies in the regenerative medicine field, has landed $2,377,802. It still seeks $5,622,198, according to the regulatory filing. The company is in a quiet period of funding right now, Chairman of the Board Dr. Steve Davis said. That period should end Aug. 5, so be […]
Cleveland-based Athersys (NYSE:ATHX) has a full plate as it continues to advance its “off the shelf” stem cell therapy, MultiStem, through clinical trials in several indications. That means shareholders can expect more R&D spending and potential new partnerships this year as the company continues developing MultiStem and its 5HT2C agonist program. Athersys CEO Gil Van […]
A University of Texas spinoff company has pulled in $2 million to test a new technique for culturing non-embryonic stem cells. According to a regulatory filing, StemBioSys raised at least $2 million of a $3.5 million equity offering. A company representative was not available to elaborate, but CEO Dr. Steven Davis told the San Antonio […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
It’s easy to look at Nobel Prize winners and assume the greatness of their work. But it’s even more awe-inspiring to understand the research and see it in action. This year, the Nobel Prize in physiology or medicine was given to regenerative medicine researchers Sir. John B. Gurdon of the University of Cambridge and Shinya […]
A California regenerative medicine firm raised $9.2 million and is planning new clinical trials for its stem cell modulator in patients with blood cancer. Read more.
A cure for spinal cord injury? Diabetes? Macular degeneration? Hope or just hype? There are now some clinical trials using embryonic stem cells to treat serious diseases for which no other good therapy is currently available. But this is just the beginning of a major medical megatrend that will blossom forth in the coming years. […]
Last summer, when regenerative medicine company Stem Cell Theranostics went through the StartX accelerator program at Stanford University along with one other biotech company, the team members realized that many aspects of their experiences were much different than those of the other companies. For example, they weren’t moving as quickly as the other companies, and […]
For just a second, let’s stop thinking about the future of medicine in terms of post-healthcare reform and post-2012 election. Let’s think like emerging technology strategist Michell Zappa did when he put together a graphic based on what major technologies he sees — by “looking at emerging trends and research” — becoming mainstream in the […]